Home/ Stocks/ CGEM

Cullinan Therapeutics, Inc. Common Stock

CGEM XNAS

$17.73 -0.22 (-1.23%) ▼ 15-min delayed

Open

$18.14

High

$18.43

Low

$17.39

Volume

361.8K

Market Cap

$1.16B

About Cullinan Therapeutics, Inc. Common Stock

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 109 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-49,661,000	N/A
FY 2025	$0	$-219,879,000	N/A
Q3 2025	$0	$-50,610,000	N/A
Q2 2025	$0	$-70,055,000	N/A

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for CGEM yet. Check out our latest market news or earnings calendar.

Get CGEM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cullinan Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.